Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microtransplantation and Nivolumab in Relapsed/Refractory B Cell Lymphomas
NCT03920631Phase 1Withdrawn
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in B cell lymphoma (4 cohorts). Primary endpoints: Maximum Tolerated Dose at 1.5 years, Incidence of Dose Limiting Toxicity at 4 years and 1 more. Planned start Jul 2020; status: withdrawn.
02
Drugs
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03920631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920631.